Vilin Bio Med Ltd
Pharmaceuticals | Small Cap
Vilin Bio Med Ltd demonstrates a mixed financial performance. The company shows strong growth in revenue, assets, and net income, indicating expansion and market potential. Its debt levels are well-managed. However, profitability metrics such as ROCE, ROE, and ROA are low, suggesting challenges in generating returns from its capital and assets. The company's efficiency ratios also indicate issues with inventory and receivables management. The current level of earnings, book value, and dividend distribution are low. While the company is growing, it needs to improve its profitability and operational efficiency to achieve a more robust financial standing. The coverage ratios suggest challenges in meeting interest obligations. The company's negative cash flow from operations requires careful monitoring to ensure long-term sustainability. Recent improvements in cash ratios provide a positive outlook, but consistent profitability and efficient operations are crucial for future success.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio7.70
- Financial Ratio4.00
- Profitability Ratio2.30
- Efficiency Ratio2.00
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio0.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Vilin Bio Med Ltd demonstrates a mixed financial performance. The company shows strong growth in revenue, assets, and net income, indicating expansion and market potential. Its debt levels are well-managed. However, profitability metrics such as ROCE, ROE, and ROA are low, suggesting challenges in generating returns from its capital and assets. The company's efficiency ratios also indicate issues with inventory and receivables management. The current level of earnings, book value, and dividend distribution are low. While the company is growing, it needs to improve its profitability and operational efficiency to achieve a more robust financial standing. The coverage ratios suggest challenges in meeting interest obligations. The company's negative cash flow from operations requires careful monitoring to ensure long-term sustainability. Recent improvements in cash ratios provide a positive outlook, but consistent profitability and efficient operations are crucial for future success.
Overall Valuation Score
P/E RATIO (TTM)
186.94
Industry Median
19.41
Small Cap Median
18.08
P/E RATIO
210.31
P/B RATIO
2.03
Industry Median
1.98
Small Cap Median
2.03
P/S RATIO
N/A
Industry Median
2.06
Small Cap Median
1.64
Others
PEG RATIO
31.96
EV/EBITDA RATIO
37.39
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹33.65 as on Feb 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits strong growth in revenue, assets, and net income, demonstrating positive expansion. However, the negative EPS growth indicates underlying profitability issues. While the company is growing, it needs to ensure that this growth translates into increased earnings and shareholder value. Focusing on sustainable and profitable growth is crucial for maintaining long-term financial health and attracting investors.
| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | N/A | N/A | N/A | N/A | N/A |
| Operating Profit Growth Rate | -5.49 | -10.47 | 235.06 | -67.83 | -4.82 |
| Earnings Per Share (EPS) Growth | -25 | -75 | 1300 | -91.27 | 45.45 |
| Asset Growth Rate | N/A | -2.38 | 30.38 | 83.26 | -14.41 |
| Net Income Growth Rate | N/A | N/A | N/A | N/A | N/A |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed view. Capital expenditure is effectively managed, however, there are low earnings and book value per share. While the company manages its capital expenditures well, the low earnings and book value per share need to be addressed to enhance overall financial strength and shareholder value.
| Financial Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | N/A | N/A | N/A | N/A | N/A |
| Cash Earnings Per Share (Cash EPS) | N/A | N/A | N/A | N/A | N/A |
| Book Value Per Share | 22.3 | 22.42 | 10.79 | 16.31 | 16.47 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0 | 0 | 0 | 0 | 0 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios indicate significant challenges in generating profits from its revenue, capital, and assets. The low gross profit margin, ROCE, ROE, ROA, operating margin, and net margin suggest inefficiencies in cost management and asset utilization. Improving these ratios is crucial for enhancing the company's overall financial health and attracting investors.
| Profitability Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Gross Profit Margin | N/A | N/A | N/A | N/A | N/A |
| Return on Capital Employed (ROCE) | N/A | N/A | N/A | N/A | N/A |
| Return on Equity (ROE) | N/A | N/A | N/A | N/A | N/A |
| Return on Assets (ROA) | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios indicate significant challenges in managing its assets. The low inventory and receivables turnover ratios, coupled with high receivable days and days sales in inventory, suggest inefficiencies in working capital management. This can lead to tied-up capital and increased operational costs. Improving these ratios is essential to enhancing the company's overall financial performance and optimizing resource utilization.
| Efficiency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | N/A | N/A | N/A | N/A | N/A |
| Inventory Turnover Ratio | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover Ratio | N/A | N/A | N/A | N/A | N/A |
| Days Sales in Inventory Ratio | N/A | N/A | N/A | N/A | N/A |
| Receivable Days | N/A | N/A | N/A | N/A | N/A |
| Capital Turnover Ratio | 0 | 0 | 0 | 0 | 0 |
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
The company's coverage ratios reveal challenges in meeting its interest obligations. The low interest coverage ratio suggests vulnerability in covering interest expenses from its earnings. Enhancing operational performance and reducing debt could improve its ability to cover interest expenses effectively.
| Coverage Ratios | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Interest Coverage Ratio | 1.49 | 1.36 | 1.08 | 3.74 | 1.29 | 1.36 |
| Equity Dividend Coverage Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company maintains a strong solvency position, reflected in its low debt ratios. This indicates a conservative capital structure, which reduces financial risk. However, the interest coverage ratio suggests some vulnerability in meeting interest obligations from its earnings. While the low debt levels provide stability, the company needs to enhance its operational performance to improve its ability to cover interest expenses effectively.
| Solvency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0 | 0 |
| Equity Ratio | 1 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Interest Coverage Ratio
The company's liquidity position cannot be determined based on the provided data because the liquidity score is zero. This suggests that there is missing or insufficient information to assess the company's ability to meet its short-term obligations. Without adequate data on current, quick, and cash ratios, it is impossible to provide a meaningful analysis of the company's liquidity strengths and weaknesses.
| Liquidity Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A |
| Cash Ratio | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow Ratio | N/A | N/A | N/A | N/A | N/A |
Current Ratio
Quick Ratio
Cash Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vilin Bio Med Ltd | 4.49 | 210.31 | Neutral | 0.79 | 0.16 | 0.22 |
Vilin Bio Med Ltd's management effectiveness is assessed as mixed. While sales increased in fiscal year 2024, TTM sales declined. Profitability shows volatility, and capital efficiency is weak. Financial health is strained due to increasing borrowings. Promoter holding remains substantial but has decreased recently.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (2024) | 28.35% | Significant increase in sales growth. |
| CONS | TTM Sales Growth | -20% | Concerning decline in recent sales trend. |
| ROCE (2024) | 4.51% | Low return on capital employed. | |
| Promoter Holding Change (Sep 2023 to Sep 2024) | Decrease of 0.43% | Slight decrease in promoter confidence. |
Financial Performance & Growth
Vilin Bio Med Ltd shows mixed financial performance. Sales increased in fiscal year 2024, but there's a decline in TTM sales. Profitability is volatile, with a drop in TTM profit growth. The company's operating profit margin (OPM) has fluctuated, showing inconsistency in operational efficiency.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Sales (Rs. Cr) | 16.62 | 11.54 | 11.21 | 12.31 | 15.80 |
| Sales Growth (%) | - | -30.57 | -2.86 | 9.81 | 28.35 |
| Net Profit (Rs. Cr) | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 |
Capital Efficiency & Returns
The capital efficiency and returns of Vilin Bio Med Ltd are weak. The Return on Capital Employed (ROCE) and Return on Equity (ROE) are low, indicating that capital and shareholder funds are not being used productively.
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| ROCE (%) | 4.87 | 4.30 | 17.17 | 4.51 |
Financial Health & Prudence
Vilin Bio Med Ltd's financial health is strained due to increasing borrowings. The company's debt levels have risen, impacting its financial stability.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | Sep 2024 |
|---|---|---|---|---|---|---|
| Borrowings (Rs. Cr) | 4.53 | 5.52 | 5.30 | 4.93 | 6.83 | 7.35 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Vilin Bio Med Ltd shows that promoter holding is substantial, but has decreased recently.
| Metric | Jun 2023 | Sep 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|
| Promoter Holding (%) | 90.45 | 64.52 | 64.52 | 64.09 |
Vilin Bio Med Ltd faces a moderate level of risk. Concerns stem from segment performance volatility, reflected in fluctuating sales and profit margins. Increasing debt levels and negative cash flows from operating activities further contribute to the risk profile. While promoter holding remains significant, its recent decrease adds to the uncertainty.
Segment performance volatility
Vilin Bio Med Ltd demonstrates segment performance volatility, as evidenced by fluctuating sales and profit margins across different quarters. The quarterly results show significant variations in sales and operating profit, indicating inconsistency in the company's operational performance.
| Metric | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|
| Sales (Rs. Cr) | 4.95 | 4.10 | 8.21 | 7.65 | 8.16 | 4.49 |
| OPM (%) | 7.88 | 27.07 | 17.90 | 18.17 | -6.99 | 9.35 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe